Search Results - "Ko, Ryo"

Phase II study of nab‐paclitaxel + carboplatin for patients with non‐small‐cell lung cancer and interstitial lung disease by Kenmotsu, Hirotsugu, Yoh, Kiyotaka, Mori, Keita, Ono, Akira, Baba, Tomohisa, Fujiwara, Yutaka, Yamaguchi, Ou, Ko, Ryo, Okamoto, Hiroaki, Yamamoto, Nobuyuki, Ninomiya, Takashi, Ogura, Takashi, Kato, Terufumi

“…The prognosis of non‐small‐cell lung cancer (NSCLC) patients with interstitial lung disease (ILD) is poor, and 5%‐20% of those receiving chemotherapy…”
Get full text

Isolation and molecular analysis of circulating tumor cells from lung cancer patients using a microfluidic chip type cell sorter by Watanabe, Masaru, Kenmotsu, Hirotsugu, Ko, Ryo, Wakuda, Kazushige, Ono, Akira, Imai, Hisao, Taira, Tetsuhiko, Naito, Tateaki, Murakami, Haruyasu, Abe, Masato, Endo, Masahiro, Nakajima, Takashi, Koh, Yasuhiro, Takahashi, Toshiaki

“…Circulating tumor cells (CTCs) are a tumor‐derived material utilized for liquid‐based biopsy; however, capturing rare CTCs for further molecular analysis…”
Get full text

Association between the efficacy and immune-related adverse events of pembrolizumab and chemotherapy in non-small cell lung cancer patients: a retrospective study by Kurokawa, Kana, Mitsuishi, Yoichiro, Shimada, Naoko, Kawakami, Yuta, Miura, Keita, Miyawaki, Taichi, Asao, Tetsuhiko, Ko, Ryo, Shukuya, Takehito, Shibayama, Rina, Nojiri, Shuko, Takahashi, Kazuhisa

“…Abstract Background The combination of immune-checkpoint inhibitors with chemotherapy has become the standard of treatment for non-small cell lung cancer…”
Get full text

Efficacy of second-line chemotherapy in patients with pulmonary large cell neuroendocrine carcinoma by Iida, Yuko, Wakuda, Kazushige, Kenmotsu, Hirotsugu, Doshita, Kosei, Kodama, Hiroaki, Nishioka, Naoya, Miyawaki, Eriko, Miyawaki, Taichi, Mamesaya, Nobuaki, Kobayashi, Haruki, Omori, Shota, Ko, Ryo, Ono, Akira, Naito, Tateaki, Murakami, Haruyasu, Sugino, Takashi, Gon, Yasuhiro, Takahashi, Toshiaki

“…The efficacy of second-line chemotherapy in patients with pulmonary large cell neuroendocrine carcinoma (LCNEC) is unclear. This study aimed to evaluate the…”
Get full text

Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure by Sasaki, Shinichi, M.D., Ph.D, Yoshioka, Yasuko, M.D., Ph.D, Ko, Ryo, M.D., Ph.D, Katsura, Yoko, M.D., Ph.D, Namba, Yukiko, M.D., Ph.D, Shukuya, Takehito, M.D., Ph.D, Kido, Kenji, M.D., Ph.D, Iwakami, Shinichiro, M.D., Ph.D, Tominaga, Shigeru, M.D., Ph.D, Takahashi, Kazuhisa, M.D., Ph.D

“…Abstract Background Epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitors (TKIs) have been successfully used to treat patients with non-small…”
Get full text

A Novel Therapeutic Strategy Targeting the Mesenchymal Phenotype of Malignant Pleural Mesothelioma by Suppressing LSD1 by Wirawan, Aditya, Tajima, Ken, Takahashi, Fumiyuki, Mitsuishi, Yoichiro, Winardi, Wira, Hidayat, Moulid, Hayakawa, Daisuke, Matsumoto, Naohisa, Izumi, Kenta, Asao, Tetsuhiko, Ko, Ryo, Shimada, Naoko, Takamochi, Kazuya, Suzuki, Kenji, Abe, Masaaki, Hino, Okio, Sekido, Yoshitaka, Takahashi, Kazuhisa

“…Malignant pleural mesothelioma (MPM) is a highly aggressive tumor that has a low overall survival; however, no significant treatment advances have been made in…”
Get full text

Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients by Ko, Ryo, Kenmotsu, Hirotsugu, Serizawa, Masakuni, Koh, Yasuhiro, Wakuda, Kazushige, Ono, Akira, Taira, Tetsuhiko, Naito, Tateaki, Murakami, Haruyasu, Isaka, Mitsuhiro, Endo, Masahiro, Nakajima, Takashi, Ohde, Yasuhisa, Yamamoto, Nobuyuki, Takahashi, Kazuhisa, Takahashi, Toshiaki

“…The majority of non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation eventually develop resistance to EGFR…”
Get full text

Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study by Miyawaki, Taichi, Kenmotsu, Hirotsugu, Kodama, Hiroaki, Nishioka, Naoya, Miyawaki, Eriko, Mamesaya, Nobuaki, Kobayashi, Haruki, Omori, Shota, Ko, Ryo, Wakuda, Kazushige, Ono, Akira, Naito, Tateaki, Murakami, Haruyasu, Mori, Keita, Harada, Hideyuki, Endo, Masahiro, Takahashi, Kazuhisa, Takahashi, Toshiaki

“…Local ablative therapy (LAT) may be beneficial for patients with epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) with…”
Get full text

Long-term survival data of patients with limited disease small cell lung cancer: a retrospective analysis by Doshita, Kosei, Kenmotsu, Hirotsugu, Omori, Shota, Tabuchi, Yuya, Kawabata, Takanori, Kodama, Hiroaki, Nishioka, Naoya, Miyawaki, Eriko, Iida, Yuko, Miyawaki, Taichi, Mamesaya, Nobuaki, Kobayashi, Haruki, Ko, Ryo, Wakuda, Kazushige, Ono, Akira, Naito, Tateaki, Murakami, Haruyasu, Mori, Keita, Harada, Hideyuki, Kaneko, Takeshi, Takahashi, Toshiaki

“…Summary Introduction : In patients with limited disease small cell lung cancer (LD-SCLC) treated with concurrent chemoradiotherapy (CCRT), long-term survival…”
Get full text

Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status by Nakashima, Kazuhisa, Kimura, Madoka, Akamatsu, Hiroaki, Daga, Haruko, Imai, Hisao, Taira, Tetsuhiko, Ko, Ryo, Hisamatsu, Yasushi, Nishino, Kazumi, Sugimoto, Takeya, Miyashita, Yosuke, Takahashi, Toshiaki

“…Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that is effective against EGFR T790M…”
Get full text

Suitability of frozen cell pellets from cytology specimens for the Amoy 9‐in‐1 assay in patients with non‐small cell lung cancer by Kodama, Hiroaki, Murakami, Haruyasu, Mamesaya, Nobuaki, Kobayashi, Haruki, Omori, Shota, Wakuda, Kazushige, Ko, Ryo, Ono, Akira, Kenmotsu, Hirotsugu, Naito, Tateaki, Matsumoto, Shingo, Goto, Koichi, Shimizu, Tetsuo, Gon, Yasuhiro, Takahashi, Toshiaki

“…Background The AmoyDx Pan lung cancer PCR panel (AmoyDx PLC panel) has been approved as a companion diagnostic tool for multiple anticancer agents in patients…”
Get full text

Activation of insulin‐like growth factor‐1 receptor confers acquired resistance to osimertinib in non‐small cell lung cancer with EGFR T790M mutation by Hayakawa, Daisuke, Takahashi, Fumiyuki, Mitsuishi, Yoichiro, Tajima, Ken, Hidayat, Moulid, Winardi, Wira, Ihara, Hiroaki, Kanamori, Koichiro, Matsumoto, Naohisa, Asao, Tetsuhiko, Ko, Ryo, Shukuya, Takehito, Takamochi, Kazuya, Hayashi, Takuo, Suehara, Yoshiyuki, Takeda Nakamura, Ikuko, Ueno, Toshihide, Kohsaka, Shinji, Mano, Hiroyuki, Takahashi, Kazuhisa

“…Background Osimertinib (AZD9291) is a third‐generation EGFR‐tyrosine kinase inhibitor (TKI) that selectively inhibits the activating EGFR mutation and T790M…”
Get full text

Exploring the relationship between anorexia and therapeutic efficacy in advanced lung cancer treatment: a retrospective study by Doshita, Kosei, Naito, Tateaki, Matsuda, Suguru, Morita, Meiko, Sekikawa, Motoki, Miura, Keita, Kodama, Hiroaki, Yabe, Michitoshi, Morikawa, Noboru, Iida, Yuko, Mamesaya, Nobuaki, Kobayashi, Haruki, Ko, Ryo, Wakuda, Kazushige, Ono, Akira, Murakami, Haruyasu, Kenmotsu, Hirotsugu, Takahashi, Toshiaki

“…Background Chemotherapy‐induced anorexia is a common occurrence in patients undergoing treatment for advanced lung cancer. However, the relationship between…”
Get full text

Chemotherapy-Regulated microRNA-125-HER2 Pathway as a Novel Therapeutic Target for Trastuzumab-Mediated Cellular Cytotoxicity in Small Cell Lung Cancer by Yagishita, Shigehiro, Fujita, Yu, Kitazono, Satoru, Ko, Ryo, Nakadate, Yusuke, Sawada, Takeshi, Kitamura, Yuka, Shimoyama, Tatsu, Maeda, Yoshiharu, Takahashi, Fumiyuki, Takahashi, Kazuhisa, Tamura, Tomohide, Koizumi, Fumiaki

“…Small cell lung cancer (SCLC) accounts for 15% of all lung cancer cases and is a highly lethal disease. For the last several decades, the standard treatment…”
Get full text

Clinical characteristics of adrenal insufficiency induced by pembrolizumab in non‐small‐cell lung cancer by Kurokawa, Kana, Mitsuishi, Yoichiro, Shimada, Naoko, Ito, Naoaki, Ogiwara, Misa, Miura, Keita, Asao, Tetsuhiko, Ko, Ryo, Shukuya, Takehito, Shibayama, Rina, Goto, Hiromasa, Takahashi, Kazuhisa

“…Background and Aim Immune checkpoint inhibitors have significantly improved the clinical outcomes of many cancer types, but they induce a range of…”
Get full text

Efficacy and safety of carboplatin and etoposide in older extensive‐stage small‐cell lung cancer patients with a poor performance status by Mamesaya, Nobuaki, Kodama, Hiroaki, Iida, Yuko, Kobayashi, Haruki, Ko, Ryo, Wakuda, Kazushige, Ono, Akira, Kenmotsu, Hirotsugu, Naito, Tateaki, Murakami, Haruyasu, Shimizu, Tetsuo, Gon, Yasuhiro, Takahashi, Toshiaki

“…Carboplatin plus etoposide is a standard treatment for older extensive‐stage small‐cell lung cancer (ES‐SCLC) patients with performance status (PS) 2. However,…”
Get full text

Surfactant protein-D predicts prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer: a case control study by Nakamura, Kota, Kato, Motoyasu, Shukuya, Takehito, Mori, Keita, Sekimoto, Yasuhito, Ihara, Hiroaki, Kanemaru, Ryota, Ko, Ryo, Shibayama, Rina, Tajima, Ken, Koyama, Ryo, Shimada, Naoko, Nagashima, Osamu, Takahashi, Fumiyuki, Sasaki, Shinichi, Takahashi, Kazuhisa

“…Interstitial lung diseases induced by anticancer agents (ILD-AA) are rare adverse effects of anticancer therapy. However, prognostic biomarkers for ILD-AA have…”
Get full text

Relationship between patterns of immunohistochemical conventional neuroendocrine markers and efficacy of immune check point inhibitors in patients with extensive disease small cell lung cancer by Iida, Yuko, Wakuda, Kazushige, Kawata, Takuya, Morita, Meiko, Sekikawa, Motoki, Doshita, Kosei, Yabe, Michitoshi, Kodama, Hiroaki, Miura, Keita, Morikawa, Noboru, Mamesaya, Nobuaki, Kobayashi, Haruki, Ko, Ryo, Ono, Akira, Kenmotsu, Hirotsugu, Naito, Tateaki, Murakami, Haruyasu, Gon, Yasuhiro, Takahashi, Toshiaki

“…Background Which patients benefit from the addition of immune checkpoint inhibitors (ICIs) to chemotherapy for small cell lung cancer (SCLC) remains unclear…”
Get full text

Impact of losing adipose tissue on outcomes from PD‐1/PD‐L1 inhibitor monotherapy in non‐small cell lung cancer by Nishioka, Naoya, Naito, Tateaki, Miyawaki, Taichi, Yabe, Michitoshi, Doshita, Kosei, Kodama, Hiroaki, Miyawaki, Eriko, Iida, Yuko, Mamesaya, Nobuaki, Kobayashi, Haruki, Omori, Shota, Ko, Ryo, Wakuda, Kazushige, Ono, Akira, Kenmotsu, Hirotsugu, Murakami, Haruyasu, Takayama, Koichi, Takahashi, Toshiaki

“…Background Adipose tissue induces inflammation, which desensitizes the efficacy of immunotherapy. However, several reports show that the therapeutic effect of…”
Get full text

Safety and efficacy of amrubicin with primary prophylactic pegfilgrastim as second‐line chemotherapy in patients with small cell lung cancer by Sekikawa, Motoki, Murakami, Haruyasu, Morita, Meiko, Doshita, Kosei, Miura, Keita, Kodama, Hiroaki, Morikawa, Noboru, Iida, Yuko, Mamesaya, Nobuaki, Kobayashi, Haruki, Ko, Ryo, Wakuda, Kazushige, Ono, Akira, Kenmotsu, Hirotsugu, Naito, Tateaki, Chiba, Hirofumi, Takahashi, Toshiaki

“…Background Amrubicin (AMR) regimens have shown efficacy as second‐line treatment in patients with small cell lung cancer (SCLC); however, adverse events such…”
Get full text